CorMedix Dividends and Buybacks
Dividend criteria checks 0/6
CorMedix does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-15.2%
Buyback Yield
| Total Shareholder Yield | -15.2% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Narrative Update • Apr 30
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
With ReSPECT Phase III positive this week, CRMD has resolved its single largest binary risk and now trades at a 63% discount to base case intrinsic value with a bear case floor only 8% below current price, as the REZZAYO prophylaxis sNDA path, DefenCath TPN pipeline, and post-TDAPA revenue recovery converge toward a 2027 inflection that the $7 stock price is not remotely reflecting.
Narrative Update • Apr 23
CRMD: Reaffirmed 2026 Outlook And Buyback Plan Will Support Undervalued Shares
Analysts have trimmed their 12 month price target on CorMedix to $13 from $15, reflecting updated views on revenue growth, profitability, and appropriate future P/E levels for the stock. Analyst Commentary Recent price target revisions to US$13 from US$15 sit alongside continued positive ratings, which gives a mixed message for investors.Narrative Update • Apr 06
CRMD: Investor Day Will Reframe Lower Guidance And Support Undervalued Outlook
Narrative Update on CorMedix Analysts have reduced their blended price targets on CorMedix by several dollars to a range of roughly $13 to $16, citing updated company revenue guidance that is materially below prior Street expectations, especially for DefenCath in 2026 and 2027. Analyst Commentary Street research on CorMedix has shifted toward lower valuation targets after the company issued revenue guidance for 2026 and 2027 that sits well below prior expectations, particularly for DefenCath.Seeking Alpha • Apr 02
CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade)
Summary CorMedix Inc. is upgraded to Hold, with near-term upside tied to the pivotal Phase III ReSPECT trial for Rezzayo in Q2 '26. CRMD's FY25 saw strong profitability: $163.1M net income, $401.3M pro forma revenue, and $77.2M adjusted EBITDA, aided by the Melinta acquisition. CRMD stock trades at discounted multiples (8.43x P/E, 4.38x EV/EBITDA), reflecting execution risk and conservative growth assumptions despite robust cash flow. The ReSPECT trial could unlock a $2B prophylaxis market and drive a CRMD stock valuation re-rating if results are positive. Read the full article on Seeking AlphaNew Narrative • Apr 02
CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
Investment Thesis DefenCath's regulatory moat (only FDA-approved antimicrobial CLS in the U.S., NCE+GAIN exclusivity through 2033, composition patent to 2042) is intact and the 72% real-world CRBSI reduction is standard-of-care quality data; the TDAPA pricing step-down is a commercial mechanics event, not a competitive displacement event The stock at $7.02 prices in approximately the bear case ($6.54), meaning investors are effectively receiving the REZZAYO prophylaxis Phase III binary and the DefenCath TPN pipeline for free — an unusual asymmetry for a cash-flow-positive commercial pharma company Operating cash flow of $175M in FY2025 and $148.5M in cash provides full self-funding of pipeline without dilution risk, and the $75M buyback at current prices represents management's explicit capital allocation conviction about intrinsic value The Melinta acquisition was well-priced ($30M goodwill on $391M identified intangibles) and adds an annualizing $130M+ revenue stream with shared call points that provide SG&A leverage as the combined platform scales Post-TDAPA recovery in 2027 (3x–5x higher add-on payment vs. H2 2026 per management, plus Medicare Advantage contracting upside not in guidance) provides a clearly identified catalyst path back to re-rating independent of pipeline success Risk Considerations ReSPECT Phase III failure (data Q2 2026) would eliminate ~$221M of base case rNPV, trigger impairment of the $143M IPR&D intangible, and likely reset the stock to the $5.60 52-week low or below — this is the primary binary risk and is near-term Customer concentration at 79% revenue from three accounts is structurally dangerous; any publicly announced reduction in DefenCath orders from a major dialysis organization would be a material negative event with little warning The Q4 GAAP EPS miss ($0.16 vs.Narrative Update • Mar 22
CRMD: Investor Day Will Clarify Lower Guidance And Highlight Perceived Upside
Analysts have trimmed CorMedix price targets by $2 to $9, with recent cuts such as $20 to $16 and $15 to $13, reflecting updated views on DefenCath revenue guidance and the company outlook shared in recent research notes. Analyst Commentary Recent research reflects a reset in expectations for CorMedix as analysts align their models with the latest DefenCath revenue guidance and management commentary.Narrative Update • Mar 08
CRMD: Investor Day Reset On Lower Guidance Will Highlight Undervalued Upside
Narrative Update on CorMedix The analyst price target for CorMedix has been trimmed from about $14.86 to roughly $14.57. Analysts are recalibrating their models in light of lower revenue growth and margin expectations, along with a more conservative view on long term DefenCath contribution, as reflected in recent target cuts from $20 to $16, $15 to $13, and other reductions across the Street.Narrative Update • Feb 21
CRMD: Investor Day Will Reframe Lower Guidance And Support Undervalued Thesis
Analysts have trimmed their average price targets on CorMedix by a mid single digit dollar amount, citing the company's new FY26 and 2027 DefenCath revenue guidance, which sits well below prior Street expectations, as a key driver of their revised views. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside even with price targets trimmed, suggesting they view the lower guidance as already influencing valuation assumptions.Narrative Update • Feb 07
CRMD: Investor Day And New Revenue Guidance Will Shape Bullish Case
Analysts have trimmed their price targets on CorMedix, with our fair value estimate moving from US$16.86 to US$14.86 as they factor in lower revenue growth and profit margin assumptions, despite a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential in CorMedix shares, pointing to the higher future P/E multiple being used in their models as a sign that they are willing to ascribe a premium to the company despite reduced revenue assumptions.Analysis Article • Feb 06
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%
The CorMedix Inc. ( NASDAQ:CRMD ) share price has fared very poorly over the last month, falling by a substantial 35...Narrative Update • Jan 22
CRMD: Updated Revenue Guidance And Investor Day Will Shape Upside Potential
Narrative Update Analysts have trimmed their average price target for CorMedix from about US$19 to roughly US$16.86. This reflects updated expectations for slower revenue growth and lower profit margins, partially offset by a higher assumed future P/E multiple following the company's reduced long term guidance and recent research updates.Narrative Update • Jan 07
CRMD: Robust Q3 Sales And Synergy Progress Will Support Further Upside
Narrative Update: CorMedix Analysts have maintained their fair value estimate for CorMedix at $19.00. Recent Street research highlights a $14.00 price target supported by what they describe as "robust" preliminary Q3 sales, better visibility into near term operating synergies, and the recent stock pullback.Analysis Article • Dec 23
CorMedix Inc.'s (NASDAQ:CRMD) 28% Jump Shows Its Popularity With Investors
CorMedix Inc. ( NASDAQ:CRMD ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...Narrative Update • Dec 14
CRMD: Robust Q3 Sales Will Support Stronger Upside Momentum Ahead
Analysts have modestly raised their price target on CorMedix to $19.00 from $14.00, citing robust preliminary Q3 sales, clearer visibility into near term operating synergies, and the recent stock pullback as key drivers of their more constructive outlook. Analyst Commentary Bullish Takeaways Bullish analysts highlight that robust preliminary Q3 sales provide early validation of CorMedix's commercial strategy and support the raised price target.Narrative Update • Nov 28
CRMD: Q3 Sales Strength And New Buy Rating Will Drive Momentum Forward
Analysts have raised their price target for CorMedix to $14 from the previous level, citing stronger than expected Q3 sales and improved visibility into operational performance as key drivers of the updated outlook. Analyst Commentary Following the recent preliminary Q3 results, analysts have provided updated insights into CorMedix’s outlook, highlighting both encouraging signs and ongoing areas of caution for the company’s future performance.Narrative Update • Nov 14
CRMD: Strong Q3 Sales Will Drive Renewed Uptrend Momentum
Analysts have lowered their price target for CorMedix from $20.40 to $19.00, citing a more moderate revenue growth outlook and adjusted profit expectations. This comes despite optimism about robust Q3 sales and operational improvements.Narrative Update • Sep 04
Acquisition And Pipeline Expansion Will Unlock Healthcare Potential
CorMedix’s consensus price target has edged up to $20.40, as analysts see greater revenue potential from DefenCath’s accelerating launch, expanded patient uptake, and supportive reimbursement dynamics, offsetting equity-related dilution concerns. Analyst Commentary The recent $85M equity offering extends CorMedix's cash runway but introduces dilution, prompting a reduced price target from previous levels based on valuation concerns.Analysis Article • Aug 14
Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position
The latest earnings release from CorMedix Inc. ( NASDAQ:CRMD ) disappointed investors. Our analysis found several...Analysis Article • Aug 09
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD)
NasdaqGM:CRMD 1 Year Share Price vs Fair Value Explore CorMedix's Fair Values from the Community and select yours With...Analysis Article • Jun 27
Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Celebrations may be in order for CorMedix Inc. ( NASDAQ:CRMD ) shareholders, with the analysts delivering a significant...
New Narrative • Apr 30
DefenCath Launch Will Boost Inpatient And Dialysis Opportunities
Strong revenue growth prospects from DefenCath's successful launch and expansion into new segments like inpatient facilities and partnerships.Seeking Alpha • Mar 26
The Hidden Risks Behind CorMedix's First Profitable Quarter
Summary CorMedix Inc.'s DefenCath reduces catheter infections by 71%, but the limited market potential challenges long-term adoption. Early strong revenues likely reflect inventory building rather than sustained utilization patterns. Special reimbursements boosting current profits will expire, threatening future margins and pricing power. Half-year guidance signals limited visibility, with management warning of inventory adjustments and price erosion. Monte Carlo simulations suggest CRMD faces more downside risk (25%) than upside potential (8.8%). Read the full article on Seeking AlphaAnalysis Article • Jan 17
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. Indeed, CorMedix...Seeking Alpha • Jan 07
CorMedix: Finally In Commercialization Mode
Summary CorMedix Inc.'s DefenCath, an antimicrobial catheter lock solution, shows considerable promise in reducing catheter-related bloodstream infections. The product was approved earlier this year and has seen solid initial sales traction. Analyst firms are optimistic about the company's prospects, even as the stock is down just over a third from recent highs. An analysis of CorMedix follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Dec 13
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark
When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales...Analysis Article • Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns
Key Insights CorMedix to hold its Annual General Meeting on 21st of November CEO Joe Todisco's total compensation...Analysis Article • Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
Celebrations may be in order for CorMedix Inc. ( NASDAQ:CRMD ) shareholders, with the analysts delivering a significant...Seeking Alpha • Oct 28
CorMedix 2.0: New Leadership, New Approval, New Focus
Summary CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath. The company has faced challenges in the past, including management issues and regulatory delays, but now warrants a fresh look and valuation as the company executes on commercialization. DefenCath offers a unique solution for preventing catheter-related bloodstream infections, with the potential to reduce costs and save lives. Read the full article on Seeking AlphaSeeking Alpha • Oct 19
CorMedix: Delayed Approval, Low Cash, Good Prospects
Summary CorMedix's DefenCath, an FDA-approved antimicrobial catheter lock solution, significantly reduces catheter-related bloodstream infections, addressing a critical need in hemodialysis patients. DefenCath's market exclusivity and reimbursement strategies position it well in the growing $2.6bn CRBSI market, with significant potential for revenue. Despite past challenges, CorMedix's financial outlook is improving, but additional funds are needed for future trials in new indications. Investors should await Q3 earnings data for a clearer picture, as current stock spikes are driven by DefenCath's recent launch. Read the full article on Seeking AlphaAnalysis Article • Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, CorMedix...Analysis Article • Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Feb 25
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CRMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRMD's dividend payments have been increasing.
Dividend Yield vs Market
| CorMedix Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (CRMD) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Pharmaceuticals) | 2.2% |
| Analyst forecast (CRMD) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate CRMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CRMD's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CRMD has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 20:55 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CorMedix Inc. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Butler | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |